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Proximate versus nonproximate risk factor
associated primary deep venous thrombosis:
Clinical spectrum and outcomes
Peter K. Henke, MD, Eric Ferguson, MD, Manu Varma, BS, K. Barry Deatrick, MD,
G. Thomas W. Wakefield, MD, and Derek T. Woodrum, MD, Ann Arbor, Mich
Objective: Although the treatment for acute deep vein thrombosis (DVT) is uniform, the circumstances under which it
develops vary widely and may impact outcomes. This study compared clinical features and outcomes in patients who
developed a primary DVT associated with a defined risk to those without any proximate risk factor.
Methods: Consecutive patients with a primary DVT and no past venous thromboembolism history from 2000 to 2002
were abstracted for demographics, risk factors, DVT anatomical characteristics, treatment, and outcomes of death and
new pulmonary embolism. Comparison between patients with a proximate risk event within 30 days of DVT (Inpt) and
those presenting with DVTwith no defined proximate event (Outpt) was done by univariable andmultivariable statistics.
A validated survey was mailed to all living patients to assess long-term sequela.
Results: A total of 293 patients with a mean age of 55 years and 49% men had confirmed DVT by objective means (92%
duplex) with a mean follow-up of 25  21 months. Inpts were more likely to have recent surgery or blunt trauma,
bilateral DVT, less use of low molecular weight heparin (LMWH), and new pulmonary emboli (all P<.05). Outpts with
DVT were more likely to have a history of malignancy, tibial-popliteal DVT compared with iliofemoral DVT, higher use
of LMWH, and coumadin. However, there was no difference in mortality. From the patient survey (21% response),
Outpts were more likely than Inpts to develop later varicosities and have daily frustration related to their legs (P < .05),
but no difference in edema or ulceration. Considering the entire group, independent factors associated with freedom from
PE included ambulation (odds ratio [OR]  2.3; 95% confidence interval [CI]  1.1-5.0; P  .04) while bilateral DVT
(OR  .26; 95% CI  .09-.76; P  .013) or subcutaneous heparin (OR  22; 95% CI  .05-.98; P  .047) were
associated with greater risk. Independent factors associated with survival included ambulation (OR  3.0; 95% CI 
1.3-7.2; P  .02), Coumadin use (OR  2.7; 95% CI  1.2-6.1; P  .015), and tibiopopliteal DVT (OR  2.4; 95% 
1.1-5.5; P .03), while malignancy (OR 0.1; 95% CI .05-.24; P< .01) and myocardial infarction (OR 0.12; 95%
CI  .01-.92; P  .04) were associated with lower survival.
Conclusion: Patients who develop DVT related to a defined proximate risk event (Inpt) generally have more extensive
DVT, an increased risk of PE, but less long-term functional morbidity and no difference in long-termmortality compared
to those with no proximate risk. ( J Vasc Surg 2007;45:998-1007.)The treatment for acute deep vein thrombosis (DVT) is
relatively uniform and has well defined evidence based
recommendations for prophylaxis and treatment.1,2 With
the advent of low molecular weight heparin (LMWH),
graded compression hose, and accessible use of duplex
ultrasonography, the consequences of DVT, such as pul-
monary embolism (PE) and postthrombotic syndrome
(PTS), should be lessened. However, recent epidemiologic
data suggest that overall rates of venous thromboembolism
(VTE) are similar to what they have been over the last half
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998decade despite these new advancements3(and unpublished
observations).
Patient risk factors for DVT are well documented and
include malignancy, certain medications such as oral con-
traceptives, postsurgical or trauma state, genetic hyperco-
agulable disorders, or a combination thereof.3,4 Patients
who clinically manifest DVT probably have a two hit bio-
logic phenomena.5 For example, a patient with an under-
lying genetic risk for DVT who then undergoes major
surgery may manifest DVT that otherwise would not have
occurred. Both medical illness and postsurgical states con-
fer a similar significant acquired DVT risk3,6, as these
patients are often immobile and have other systemic inflam-
matory processes occurring. Two reviews from our own
institution using an administrative database (unpublished
data, submitted) suggest that medical patients may have
slightly higher risk, perhaps because medical patients have
been historically less likely to receive adequate DVT pro-
phylaxis.7
The pathophysiology of DVT remains essentially con-
sistent with what Virchow described in the 1800s, includ-
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of local and systemic inflammation has been recognized,
both in the causation and resolution of DVT.8,9 The bio-
logical characteristics of clinical DVT have not been well
differentiated for several reasons, including the fact that
most are treated in a similar therapeutic manner, a lack of
vein-thrombus pathological specimens, and the inability to
ethically study untreated or nonprophylaxed DVT patients.
Further, the long-term outcomes of DVT have only shown
differences in relation to thrombus burden and lysis times,
but not necessarily related risk factors.10-12 For example,
some patients with an iliofemoral DVT may have full reso-
lution while some DVT never recannalize (as documented
by serial duplex studies), despite presumably similar thera-
pies, and, thus, a different propensity for PTS.11,13,14 The
underlying reasons for these differences in DVT resolution
may be determined by a number of factors including genet-
ics, how rapidly the patient is treated with anticoagulation
(and limb compression), or the circumstances by which the
DVT develops.
This study evaluated clinical features and outcomes of
patients who develop a primary DVT while hospitalized,
compared to those who presented with a primary DVT
without any defined antecedent risk event 30 days prior,
presenting as outpatients. Factors related to occurrence of
documented de novo PE are also examined.
METHODS
All patients who were seen at the University of Michi-
gan Hospitals via the emergency room or floor admission
and had an ICD-9CM diagnosis code for DVT (440.41,
.42, .43) were reviewed between 2000 and 2002. Fol-
low-up data were obtained with the use of the electronic
medical chart, as well as a validated quality of life survey
(mailed twice if the patient did not respond).15,16
Nonproximate event (Outpt) DVT were defined as
patients that were diagnosed in the emergency room or in
the clinic with primary DVT who had no documented
antecedent direct surgical or traumatic event documented
within 30 days of diagnosis. However, patients having a
history of surgery or trauma beyond 30 days, with subse-
quent admission with a DVT were included in the Outpt
group. Proximate event (Inpt) DVT were those patients
who were diagnosed with a DVT while admitted on a
medical or surgical service or having a surgery or hospital-
ization within 30 days of the diagnosis of DVT. A docu-
mented history of hypercoagulable state did not constitute
a proximate event, as there is no time limit associated with
this. Exclusions included those patients with upper extrem-
ity, soleal or gastrocnemius DVTs, and those with a docu-
mented prior history of VTE. Of note, gastrocnemius or
soleal DVTs were not included given their low likelihood of
contributing to significant PTS long term.13 Patients who
were diagnosed with a primary pulmonary embolism (PE)
but in whom a DVT scan was not performed were also
excluded. After these exclusions, 293 of 430 patients were
included for study.Assessment of how the DVT diagnosis was made, in-
cluding physical examination findings, duplex ultrasonog-
raphy, venography, CT scan, or other means was docu-
mented. In those with duplex imaging, laterality (right or
left) and region (iliofemoral or tibial-popliteal) was docu-
mented.
Patient demographics abstracted included age, tobacco
use, comorbidities such as CHF (ejection fraction 30%)
and obesity (BMI 40), oral contraceptive (OCP) or hor-
mone replacement therapy (HRT) use, and family history
of VTE. Known hypercoagulable states such as a deficiency
of anticoagulant factors (protein C, S, and antithrombin), a
positive antiphospholipid antibody titer, as well as Factor-V
Leiden, and Prothrombin 20210A genetic mutations were
documented. Recent proximate events such as orthopedic
fractures or surgery, pregnancy, pneumonia, general sur-
gery procedure, and amputation were documented in rela-
tion to greater or less than 30 days to DVT presentation.
Postoperative events of acute myocardial infarction, bed
rest status, and pneumonia were determined from chart
review.
DVT prophylaxis was assessed for Inpts, including the
categories of early ambulation, (within 24 hours of their
procedure or illness), use of subcutaneous unfractionated
heparin (uFH), sequential compression devices (SCD),
Ted hose, LMWH, coumadin, or aspirin. DVT treatment
assessed included uFH, LMWH, coumadin, aspirin,
thrombolytic therapy, graded compression hose, and
SCDs.
Outcomes included mortality and PE that occurred
after the DVT diagnosis. Pulmonary embolism was docu-
mented with a positive imaging study such as pulmonary
computed tomography angiography, pulmonary angio-
gram, or a high probability ventilation-perfusion scan. A
modified questionnaire based on that validated by Com-
erota et al evaluated subjective and objective patients fac-
tors (fully listed in Appendix I).16 In brief, pain level,
whether compression hose were worn, presence of ulcers,
edema, amount of edema, and a Likert scale for their
subjective assessment of lower extremity pain, daily frustra-
tion, and productivity were recorded.
Comparison betweenOutpts and Inpts with DVTwere
compared by univariable and multivariable statistical anal-
ysis. Survey results were compared with univariable analysis
only. Kaplan Meier Lifeplot analysis was also done. The
statistical software SAS version 9.0 (Cary, NC) was used.
The University of Michigan IRB approved this study.
RESULTS
A total of 293 patients were evaluated (Inpt  97;
Outpts  196), with a mean age of 55 /- 16 years, and
49% were men. Mean follow up was 25 /- 21 months.
Deaths occurred in 45 patients, and new PE was diagnosed
objectively in 38 (13%) patients after their initial DVT. Risk
factors for the entire group are shown in Table I. A signif-
icant number of patients had a history of bedrest status,
malignancy, as well as recent fractures, and surgical proce-
dures (primarily orthopedic and general surgery) and use of
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in 2% of patients, and those with a hypercoagulable state
were 5.4%. Of those 13 patients with a documented hyper-
coagulable state, only one patient was in the Inpt group.
There were no pregnant patients in either group, nor were
any patients documented with prothrombin 20210A ge-
netic variant. Baselinemedications with hematologic effects
included coumadin use in 13 patients and aspirin in 22
patients.
Diagnosis of DVT was confirmed by duplex ultrasound
in 92% of all patients, with venography, CTV andMRI used
for the remaining 8%. Physical examination corroborated
this by positive limb findings in 142 patients (48%). Com-
puted tomographic venography was positive in 10 patients,
and venography was used rarely (1%). Medications used for
DVT prophylaxis for Inpts included aspirin in 26 patients,
coumadin in 13 patients, TEDs and SCD in eight patients,
LMWH in three patients, and SubQ heparin in eight pa-
tients. No significant difference in prophylaxis regiments
were noted between general and orthopedic surgery (P 
.18). Therapy for DVT included LMWH or uFH in 97%,
coumadin use in 75%, and thrombolytic therapy in 1% of
patients. Of those not able to receive heparin anticoagula-
tion, 3% underwent a vena cava filter placement.
Anatomical distribution of DVT included iliofemoral
location in 53%, and slightly more left sided (52%) than
right sided DVT were documented. Tibial popliteal DVT
was present in 67%, while bilateral DVT were observed in
6% of patients.
Comparison of patient factors between Outpt and Inpt
DVT by univariable analysis showed many major differ-
ences (Table II). Specifically, male gender, and surgery and
trauma were more common in Inpts while medical ill-
nesses such as CHF and malignancy were more common
in Outpts. Positive physical exam limb findings were
more often documented in Outpts with DVT, compared
with Inpts. Bilaterality was more common whereas tibial-
Table I. Venous thrombosis risk factors: Whole group
Factor % (N)
Nonambulatory 30 (99)
Malignancy 28 (82)
General surgery 23 (68)
Orthopedic Fx 18 (54)
Orthopedic surgery 13 (38)
OCP/HRT 12 (35)
Pneumonia 7 (20)
Myocardial infarction 2 (6)
CHF 5 (15)
Obesity (BMI  40) 5 (14)
Amputation 2 (6)
FHx VTE 2 (6)
fV Leiden 2 (6)
Protein C/S 2 (6)
Fx, fracture; OCP, oral contraceptive;HRT, hormone replacement therapy;
BMI, body mass index; FHx, family history; f, factor.popliteal DVT trended, but did not quite reach significancecomparing Inpts with Outpts (P  .06). Low molecular
weight heparin and coumadin was more commonly used in
Outpts compared with Inpts, while IV uFH was more
commonly used in Inpts. Obesity, tobacco use, or hyper-
coagulable states were not significantly different between
Inpts and Outpts. Pulmonary embolism was more com-
monly documented in Inpts but mortality was the same
between the groups.
Controlling for patient risk factors, de novo PE was
more commonly observed in those patients with bilateral
DVT, as well those receiving SubQ uFH, while freedom
from PE was significantly increased with early ambulation
(Table III).
Evaluating mortality by Kaplan Meier Lifetable analy-
sis, there was no significant difference in survival over time
comparing Inpt and Outpt groups, with overall survival
83% at 24 months (data not shown). As a group, factors
independently associated with death included malignancy,
acute myocardial infarction, and presence of bilateral DVT.
Factors associated with lower mortality included tibial-
popliteal DVT, coumadin use, and early ambulation
(Table IV).
Overall survey return of those alive was 53 patients
(21%), and selected responses are shown in Table V. Ve-
nous varicosities, as well as median limb frustration score
(1 severe to 6 none) was significantly greater in Outpts
Table III. Independent factors associated with freedom
from pulmonary embolism
Factor OR 95% CI P
Bilateral DVT 0.26 0.09 – .76 .013
SubQ uFH 0.22 0.05 – 0.98 .047
Table II. Comparison of outpatient and inpatient
characteristics
Factor Outpt % (N) Inpt % (N) P
Men 44 (86) 60 (58) .01
Ortho surg 0 (0) 36 (35) .001
Ortho Fx 8 (16) 23 (22) .001
General surg 14 (27) 41 (40) .001
CHF 9 (18) 3 (3) .02
Malignancy 32 (63) 20 (19) .02
OCP/HRT 17 (33) 1 (1) .001
Positive exam 63 (123) 20 (19) .001
Bilateral
DVT
4 (8) 11 (11) .018
R sided DVT 48 (94) 65 (63) .008
uFH 25 (49) 37 (36) .04
LMWH 79 (155) 45 (44) .001
Coumadin 81 (159) 64 (62) .001
PE 10 (19) 21 (30) .01
Death 15 (30) 15 (15) .97
Fx, fracture; OCP, oral contraceptive; HRT, hormone replacement therapy;
uFH, unfractionated heparin; PE, pulmonary embolism.Early ambulate 2.29 1.06 – 4.97 .036
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(37% to 39%) and edema was common (39% to 63%), but
not significantly different between the two groups. The self
reported amount of edema (mild  0, to severe  3) was
judged equal, and leg pain scores were also similar. Finally,
compression hose was documented in 26% of Outpts with
only 6% of Inpts at follow-up.
DISCUSSION
This study shows differences between those patients
who develop a primary DVT with an associated proximate
event compared with those with no proximate event. Most
trials that have evaluated DVT incidence and therapy have
been in the setting of specific operative procedures, ill-
nesses, or those with known hypercoagulable states and
have not considered the etiology per se. Indeed, the most
comprehensive consensus guidelines do not differentiate
therapy between DVT etiologies such as idiopathic DVT,
vs a proximate event, except in delineating length of anti-
coagulant therapy as no evidence yet exists for differences.1
Similarly, the extent of DVT plays little role in dictating
therapy, except in extreme limb threatening cases such as
phlegmasia.
Classic work by the University of Washington group
has shown that a large thrombus burden and specific ana-
tomical segments of DVT may increase risk of PTS.11,13
For example, the longer a thrombus takes to lyse and
proximal multi-segmental compared with distal DVT both
increase the long-term risk of PTS.10,17 Rapid therapeutic
anticoagulation is well established to decrease the incidence
of PE and recurrent DVT,18,19 but whether this decreases
the risk of PTS is unknown. From our study, Outpts,
presumably more delayed in receiving heparin anticoagula-
tion, would have longer times of untreated DVT. The
subjective patient response data suggest that later limb
manifestations of PTS were indeed more severe in Outpts,
although no quantitative evaluation of CEAP or venous
clinical severity scores were able to be done. Greater num-
bers of patients and longer, more complete follow-up
might have made these differences more significant. Few
studies have focused on limb PTS and rapidity of anticoag-
ulant therapy, although some studies have suggested more
aggressive thrombolytic therapy to remove the thrombus
Table IV. Independent factors associated with freedom
from mortality
Factor OR 95% CI P
Malignancy 0.10 0.05 – .24 .0001
AMI 0.12 0.01 – .92 .04
Bilateral DVT 0.33 0.1 – 1.01 .06
Tibiopopliteal DVT 2.4 1.1 – 5.5 .03
Coumadin 2.7 1.2 – 6.1 .015
Early ambulation 3.0 1.3 – 7.2 .02
AMI, acute myocardial infarctionburden as well as LMWH compared with uFH may de-crease PTS.16,20 Withholding treatment to answer this
question would not be ethically feasible, and so far, the
large multicenter trials of DVT prophylaxis21-23 have not
provided patient data regarding the long-term PTS inci-
dence in those patients who developed either symptomatic
or asymptomatic DVT as defined venographically.
The rate of postsurgical DVT/PE from a validated
prospectively maintained national database is 1.0%
(Henke PK, et al, JVS 2007; in press). Not surprisingly, few
of the Inpts who developed DVT had documented me-
chanical or pharmacological prophylaxis, despite well pub-
lished consensus guidelines.1 The reasons for nonprophy-
laxis were not specifically delineated in this study and were
directed by the primary service team. This group of patients
may have been judged to be at elevated bleeding risk,
although the rates of clinically significant bleeding with
mechanical and LMWH prophylaxis in many trials is
low.1,2,22 Others have reviewed multiple causes and pro-
posed several solutions regarding the problem of noncom-
pliance with VTE prophylaxis.24 This is also a selected
group, and we do not have the full data regarding concur-
rent hospitalized and surgical patients during this same
time. It is likely that the majority of patients admitted
during this time did have appropriate prophylaxis, and is
why they did not develop a clinical DVT.
The factors associated independently with de novo PE
were interesting. Early ambulation was historically thought
to increase the risk of PE, although that is clearly not the
case from this or other studies1,25 Bilateral DVT were
independently associated with decreased freedom from PE
by 80%. This suggests a greater thrombus burden and
perhaps impaired natural lytic mechanisms contribute to
PE. A recent registry study also confirms this association.26
Conversely, it is possible these patients were not treated as
rapidly with heparin anticoagulation as the patients with
unilateral DVT or these patients had an idiopathic in-
creased clotting potential. Prior studies have shown that
rapid therapeutic anticoagulation significantly decreases PE
in those with DVT.1,19 Unfortunately, we did not have
access to the exact timeline of diagnosis of DVT, adminis-
tration of heparin, and subsequent PE occurrence. Less
clear is why the use of prophylactic subcutaneous uFH, but
not LMWH was associated with an increased risk of PE.
One possibility is that prophylaxis of SubQ uFH was not
Table V. Patient survey results
Factor
Outpt
%
(N)
N  35
Inpt
%
(N)
N  18 P
Varicosities 49 (17) 17 (3) .04
Ulcers 11 (4) 6 (1) .65
Pain 37 (13) 39 (7) 1.0
Compression hose 26 (9) 6 (1) .14
Edema 63 (22) 39 (7) .17
Amount edema* 2 2 .93
Amount frustration* 4 6 .05
Productive* 5 5 .63*Median Likert scale
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three times a day for efficacy in high risk patients,1 but in
practice it is often just two times a day. Alternatively,
LMWH may have greater anti-inflammatory properties,
more effectively decreased thrombus formation, or pro-
moted DVT resolution, possibly via cell adhesion molecule
inhibition.9,27
Mortality in this group of patients was primarily asso-
ciated with their underlying medical illness such as malig-
nancy, or complications such as myocardial infarction.
More Outpts than Inpts had a current history of malig-
nancy, possibly because many patients receive their chemo-
therapy as outpatients, as well as the fact that DVT is often
the first presentation of a cancer.28 Much speculation exists
regarding the pathophysiology of malignancy induced hy-
percoagulability, and the type of malignancy and chemo-
therapy plays a role as well.29-31 Interestingly, the occur-
rence of myocardial infarction has been associated with
DVT12, although the overall patient numbers were small in
this study.
Bilateral DVT approached, but did not reach, signifi-
cance in association to increased mortality. Consistently,
however, a significantly lower risk of death was observed
with more distal tibiopopliteal DVT. These findings sug-
gest that overall thrombus burden likely plays a role in
mortality, although probably not directly from PE, as no
independent relationship was found between PE and mor-
tality in this group of patients. It may be that rapid and
comprehensive medical supportive therapy prevented mor-
tality. The magnitude of the PE, whether segmental or
subsegmental, was not specifically delineated, and large
studies confirm mortality of PE at 10% to 20%.32-34 Early
ambulation and coumadin use was associated with lower
mortality, but these are probably surrogate marker for
patients (a less ill group of patients who were able to
mobilize) and/or able to tolerate this form of long-term
anticoagulation. Coumadin has not been shown to de-
crease mortality in patients with malignancy compared with
LMWH in larger and longer duration studies.35 Consis-
tently, no difference in mortality was observed over time by
KM analysis between Inpts and Outpts.
Limitations of the current study include that it is retro-
spective and relies on chart abstraction of which documen-
tation is sometimes incomplete. Similarly, we did not di-
rectly interview patients and may have missed some
proximate risk events in Outpts that were not recorded in
the chart. Similarly, some of the Outpts had proximate
events prior to 30 days, but were chosen from the standard
perioperative complication time frame and from prior DVT
prophylaxis recommendations.21 As few of these patients
were seen by vascular surgeons in clinic, no assessment of
their objective limb status for CEAP class was possible. The
low survey response rate was unfortunate and may bias the
results in that the nonresponders may have either been
more or less disabled with PTS manifestations. However,
the proportion of Outpts and Inpts respondents was similar
to the overall distribution of these two groups.In conclusion, patients who develop a DVT as Inpts
compared with Outpts shared some expected and unex-
pected differences. No specific changes in current therapy
are suggested from this review, except to emphasize VTE
prophylaxis for Inpts, increased compliance with compres-
sion hose, and early ambulation when possible. A long-
term prospective patient study is underway to better delin-
eate the natural history of DVT by serum biomarker
analysis and duplex ultrasound, and the development of PE
and PTS.
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Unidentified speaker . . . Based on the title of your abstract,
your original idea was to present primary versus secondary DVT
and then now you introduce this term of inpatient and outpatient
DVT which is a new term and it does not exist in the CEEP
classification or any type of classification that we use, because it is
difficult to compare primary to secondary.
Dr Peter Henke (Ann Arbor, Mich). Right.
Unidentified speaker. So my question is, did you see a
difference in bilaterality, and I am thinking of the May-Turner
syndrome, in patients who had inpatient or outpatient or primary
or secondary DVT?
DrHenke.Thank you verymuch for your comments. Primary
DVT versus recurrent – these were all primary DVT in the sense
that the patients had no documented history of a previous venous
thromboembolism or DVT, so they are all primary in that sense.
But somewhat arbitrarily we wanted to try to define those who had
it with no discernible proximate risk factor such as surgery or
trauma versus those who did not. We did find that in the inpatients
the bilaterality of DVT was more common. One of our first
hypotheses when we were coming up with this study was that to try
to discern if early and rapid anticoagulation would prevent long-
term postthrombotic syndrome, you cannot do that ethically.
Once it is diagnosed you have to treat it, so you can’t wait orthought patients with an inpatient development of DVT might be
more rapidly treated than patients who come in, in part because of
delays or time in the emergency room and that type of thing. The
big result would be the survey in the postthrombotic syndrome,
trying to delineate that but unfortunately the the survey results
were just so poor we couldn’t do it validly.
Unidentified speaker. Could you comment on the infre-
quent use of effective prophylaxis in relatively high risk patients
______ given the published guidelines and the depth of experience
that Michigan has in DVT? It seems at odds with reality.
Dr Henke. Right. When I looked at that, I thought, boy,
that’s a low use of prophylaxis, and the thing we do not know is the
denominator of all the patients who were treated similarly over that
same period of time who did not have a DVT. This is a selected
group in a sense that they all had DVT as inpatients and their use of
prophylaxis was low. Since the time that this has come about, since
about 2004, 2005, we now have established hospital wide guide-
lines from the office of clinical affairs and Dr. Darrell Campbell
based on Joe Caprini’s risk factor score sheet and the ______
consensus guidelines. It is something that we are going to measure
as well. All patients who get admitted now get a score sheet to
make sure they at least address the risk for ______.
Unidentified speaker. Only 64% of the patients received
Coumadin _______ Can you comment on that? _______
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May 20071004 Henke et alDrHenke. The one thing I realized, of course late, was that we
did not define exactly who and who did not get a filter. Some of the
inpatients did have bleeding events which I think had them stop their
Coumadin use and I assume they got filter, but I do not know. I will
have to look back at the charts for that.WhyCoumadin use conferreda decreased risk of mortality – again it may be a surrogate that patients
whowere able to take Coumadin and not have complications had less
risk of death, whereas those who could not take Coumadin perhaps
were so ill overall and such high risk of bleeding that that again is a
surrogate for mortality or significant illness.
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1. Do you currently suffer from any of the 
a. Swelling of veins/varicose veins (dil
b. Thickening of skin    
c. Leg wounds or sores   
d. Difficulty walking    
2. Do your legs cause you pain every day?
 If yes, what is your level of pain? (Circl
1 = mild/occasional:  not restrict
  2 = moderate/daily:  some limita
  3 = severe: limits daily activities
3. Do you wear compression hose?  
 If yes, were you fitted for them 1-2 wee
 What percentage of the day do you wea
4. Have you visited a clinic/physician for w
 a. If yes, how many times in the las
     0 - 1          2 - 10       
b. How many venous ulcers have y
 ________ el and how your DVT affects your life today.  
following symptoms in your leg(s) with DVT?   
ated veins you can see)   Yes  No 
    Yes  No 
    Yes  No 
    Yes  No 
      Yes   No 
e one) 
ing activity  
tions on activity, occasional pain medication used  
, requires regular use of pain medication. 
    Yes   No 
ks after your diagnosis?   Yes   No 
r your compression hose (estimated)?      _____% 
ound care in the last year?  Yes No
t year? 
   11 - 20          21-40          > 40 
ou had in the past year?  
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May 20071006 Henke et al5. Do you currently experience leg pain when walking any distance?  Yes   No 
If yes, how far can you walk before pain occurs? 
  10 yds      50 yds      100 yds      ½ mile   1 mile 
6. Do your legs currently swell?       Yes   No 
If yes, how much do they swell?   (Circle one number) 
1 = mild: evening ankle edema 
2 = moderate: afternoon swelling above the ankle 
3 = severe: swelling in the morning, continuing up the leg throughout the day 
7. Currently or within the last year how often did the following occur?   
(Circle one number on each line) 
a. Feeling frustrated about your DVT. 
b. Feeling worn out because of your DVT  
c. Difficulty looking at your bare legs because 
of your DVT. 
d. Relied on assistance of others for day-to-
day activities because of your DVT  
e. Worry about having a DVT 
f. Wear compression hose 
All of 
the 
time 
Most
of the 
time 
A lot 
of the 
time 
Some
of the 
time 
Little 
of the 
time 
None 
of the 
time 
1 2 3 4 5 6 
1 2 3 4 5 6 
1 2 3 4 5 6 
1 2 3 4 5 6 
1 2 3 4 5 6 
1 2 3 4 5 6 
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When answering these questions, please indicate your feelings regarding each statement.   
(Circle one number on each line) 
A. I am embarrassed by the symptoms 
I experience, such as leg pain or 
changes in the appearance of my 
leg(s). 
B. I currently have to plan things 
differently because of my DVT. 
C. I avoid certain activities because of 
my DVT. 
D. I do not live a “normal” life 
because of my DVT. 
E. I am less productive at work (in 
and outside the home) now than I 
was before receiving this treatment for my DVT. 
Strongly
agree Agree 
Neither
agree 
nor 
disagree Disagree
Strongly 
disagree 
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
